{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:11:48Z","timestamp":1777551108861,"version":"3.51.4"},"reference-count":36,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2001,12,20]],"date-time":"2001-12-20T00:00:00Z","timestamp":1008806400000},"content-version":"vor","delay-in-days":353,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2001,1]]},"abstract":"<jats:p>Interleukin 4 (IL\u20104) is a pleiotropic type II cytokine which has been shown to have a direct killing effect on lymphoma and B\u2010cell chronic lymphocytic leukaemia (B\u2010CLL) cells<jats:italic>in vitro<\/jats:italic>. The clinical effects and toxicity of IL\u20104 treatment in patients with B\u2010CLL were evaluated. Fourteen patients with B\u2010CLL who were in partial remission after chemotherapy received one, two or three 8\u2010week cycles of escalating doses (2, 4 or 6\u2003\u00b5g\/kg\/d s.c.) of IL\u20104 for 3\u2003d\/week. Clinical response was analysed after each treatment cycle and toxicity was monitored continuously. Ten patients (71%) had progressive disease (PD) during IL\u20104 treatment. This was mainly attributable to an increase (two\u2010 to fourfold) of the blood lymphocyte count during IL\u20104 therapy. After cessation of IL\u20104 treatment, the lymphocytosis decreased spontaneously in 8 out of 12 evaluable patients. Splenomegaly remained unchanged in 7\/7 patients, whereas enlarged lymph nodes were reduced by &gt;\u200a50% in 1\/13 patients and by 25\u201350% in 4\/13 patients. None of the patients achieved an objective tumour regression (complete or partial remission). A temporary increase (16\u201360%) of the platelet count was observed during IL\u20104 treatment. The platelet count decreased in 8\/11 patients after the end of IL\u20104 therapy. World Health Organization (WHO) grade I\/II fever, arthralgia and fatigue was observed in one\u2010third of the patients and was more commonly seen with the highest dose (6\u2003\u00b5g\/kg\/d). One patient developed pulmonary oedema and WHO grade III neutropenia was recorded in three patients. IL\u20104 was well tolerated by most patients in an outpatient setting. The anti\u2010tumour activity observed in previous<jats:italic>in vitro<\/jats:italic>studies was not verified by the present<jats:italic>in vivo<\/jats:italic>trial which showed that IL\u20104 may instead increase the number of CLL cells in blood, indicating that IL\u20104 may have induced a stimulatory or antiapoptotic effect on the CLL cells in blood. These results may have important implications for the development of immunotherapy of CLL. In addition, the potential platelet\u2010stimulatory effect of IL\u20104 warrants further studies.<\/jats:p>","DOI":"10.1046\/j.1365-2141.2001.02525.x","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T10:10:00Z","timestamp":1027678200000},"page":"155-160","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Interleukin 4 therapy for patients with chronic lymphocytic leukaemia: a phase I\/II study"],"prefix":"10.1111","volume":"112","author":[{"given":"J.","family":"Lundin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Kimby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Karakas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Mellstedt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"\u00d6sterborg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,20]]},"reference":[{"key":"e_1_2_6_2_1","first-page":"29","article-title":"Present status of purine analogs in the therapy of chronic lymphocytic leukaemia","volume":"11","author":"Bergmann L.","year":"1997","journal-title":"Leukemia"},{"key":"e_1_2_6_3_1","first-page":"423","article-title":"The UK Medical Research Council CLL trials 1 and 2","volume":"30","author":"Catovsky D.","year":"1988","journal-title":"Nouvelle Revue Francaise D\u2019Hematologie"},{"key":"e_1_2_6_4_1","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990","article-title":"National Cancer Institute\u2010sponsored Working Group guidelines for chronic lymphocytic leukaemia. revised guidelines for diagnosis and treatment","volume":"87","author":"Cheson B.D.","year":"1996","journal-title":"Blood"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.176.5.1319"},{"key":"e_1_2_6_6_1","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1182\/blood.V79.4.990.bloodjournal794990","article-title":"Antiproliferative effects of interleukin\u20104 on freshly isolated non\u2010Hodgkin malignant B\u2010lymphoma cells","volume":"79","author":"Defrance T.","year":"1992","journal-title":"Blood"},{"key":"e_1_2_6_7_1","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1182\/blood.V89.3.941","article-title":"Chronic lymphocytic leukaemia B cells are resistant to the apoptotic effects of transforming growth factor\u2010beta","volume":"89","author":"Douglas R.S.","year":"1997","journal-title":"Blood"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0145-2126(96)00053-7"},{"key":"e_1_2_6_9_1","first-page":"93a","article-title":"Phase I studies of recombinant human interleukin\u20104 in patients with hematologic malignancies","volume":"76","author":"Freimann J.","year":"1990","journal-title":"Blood"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1989.tb07749.x"},{"key":"e_1_2_6_11_1","first-page":"433","article-title":"CHOP versus prednisolone\u2003+\u2003chlorambucil in chronic lymphocytic leukaemia (CLL): preliminary results of a randomised multicenter study","volume":"30","author":"Hansen M.M.","year":"1988","journal-title":"Nouv Rev Fr Hematol"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428199109103386"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02787339"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.10.3257"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-199112000-00005"},{"key":"e_1_2_6_16_1","first-page":"631","article-title":"The response of human B cells to interleukin 4 is determined by their stage of activation and differentiation","volume":"33","author":"Maher D.W.","year":"1991","journal-title":"Scandinavian Journal of Immunology"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0955-2235(91)90012-S"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.48.5.482"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428199509107902"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428199609054873"},{"key":"e_1_2_6_21_1","first-page":"601a","article-title":"Natural T cell immunity against autologous leukemic B cells in patient with chronic lymphocytic leukaemia \u2013 Tumour derived VH\u2010CD3 regions might be recognition structures","volume":"94","author":"Mellstedt H.","year":"1999","journal-title":"Blood"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19851115)56:10<2369::AID-CNCR2820561004>3.0.CO;2-N"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.4.1567"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1993.tb01608.x"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830260222"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1993.tb03330.x"},{"key":"e_1_2_6_27_1","first-page":"1227","article-title":"Expression and function of the FAS antigen in B chronic lymphocytic leukaemia and hairy cell leukaemia","volume":"9","author":"Panayiotidis P.","year":"1995","journal-title":"Leukemia"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.2113028.x"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(94)90009-4"},{"key":"e_1_2_6_30_1","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2141.2000.02383.x","article-title":"Autologous T lymphocytes may specifically recognize leukaemic B cells in patients with chronic lymphocytic leukaemia","author":"Rezvany M.R.","year":"2000","journal-title":"British Journal of Haematology"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002620050385"},{"key":"e_1_2_6_32_1","first-page":"197","article-title":"Recombinant human interleukin\u20104 (IL\u20104) given as daily subcutaneous injections \u2013 a phase 1 dose toxicity trial","volume":"3","author":"Scharffe J.","year":"1992","journal-title":"Annals of Oncology"},{"key":"e_1_2_6_33_1","first-page":"3692","article-title":"Interleukin 4 retards dissemination of a human B\u2010cell lymphoma in severe combined immunodeficient mice","volume":"55","author":"Schwarz M.","year":"1995","journal-title":"Cancer Research"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/icb.1997.17"},{"key":"e_1_2_6_35_1","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1182\/blood.V75.5.1114.1114","article-title":"Effects of interleukin\u20104 on the in vitro growth of human lymphoid and plasma cell neoplasms","volume":"75","author":"Taylor C.W.","year":"1990","journal-title":"Blood"},{"key":"e_1_2_6_36_1","first-page":"618","article-title":"Effect of IL\u20104 and IL\u20106 on the proliferation and differentiation of B\u2010chronic lymphocytic leukaemia cells","volume":"7","author":"Van Kooten C.","year":"1993","journal-title":"Leukemia"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01670.x"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.2001.02525.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.2001.02525.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2141.2001.02525.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T18:06:28Z","timestamp":1704305188000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2141.2001.02525.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,1]]}},"alternative-id":["10.1046\/j.1365-2141.2001.02525.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2141.2001.02525.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,1]]},"assertion":[{"value":"2001-12-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}